Alnylam Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Alnylam Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Alnylam Pharmaceuticals Inc Strategy Report
- Understand Alnylam Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for acute hepatic porphyria, Amvuttra, for the treatment of ATTR amyloidosis with cardiomyopathy; and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi drugs in the areas of genetic medicines, hepatic infectious, cardio-metabolic, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in North America, Europe and Asia-Pacific. Alnylam is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
675 W Kendall St, Cambridge, Massachusetts, 02142-1168
Website
www.alnylam.com
Telephone
1 617 5518200
No of Employees
2,100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALNY (NASD)
Revenue (2022)
$1.8B
76.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
61.1%
(2022 vs 2021)
Market Cap*
$18.7B
Net Profit Margin (2022)
XYZ
77.9%
(2022 vs 2021)
* As of and is in US$
Alnylam Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Marketed: | Onpattro |
| Onpattro - RNAi therapeutic for treatment of hATTR amyloidosis | Givlaari |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In September, the company announced the first-ever recommendations for patient- and family-centred holistic care for people living with hereditary transthyretin-mediated amyloidosis, also called hATTR or ATTRv. |
| 2023 | Contracts/Agreements | In July, the company entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension. |
| 2023 | Contracts/Agreements | In March, the company and Medison Pharma announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel. |
Competitor Comparison
| Key Parameters | Alnylam Pharmaceuticals Inc | F. Hoffmann-La Roche Ltd | AstraZeneca Plc | GSK plc | Eli Lilly and Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United Kingdom | United Kingdom | United States of America |
| City | Cambridge | Basel | Cambridge | Brentford | Indianapolis |
| State/Province | Massachusetts | - | England | England | Indiana |
| No. of Employees | 2,100 | 103,605 | 89,900 | 70,212 | 43,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Amy W. Schulman | Chairman | Executive Board | 2023 | - |
| Yvonne Greenstreet, MBChB | Director; Chief Executive Officer | Executive Board | 2022 | - |
| Jeff Poulton | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 55 |
| Indrani Franchini | Secretary; Executive Vice President; Chief Legal Officer | Senior Management | 2022 | 51 |
| Pushkal P. Garg, M.D. | Executive Vice President - Development & Medical Affairs; Chief Medical Officer | Senior Management | 2022 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward